Scarica l'app Stockscreener
551.20
0.52%
3.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$547.93
Aprire:
$545.67
Volume 24 ore:
513.12K
Relative Volume:
0.41
Capitalizzazione di mercato:
$58.49B
Reddito:
$14.09B
Utile/perdita netta:
$4.50B
Rapporto P/E:
14.03
EPS:
39.28
Flusso di cassa netto:
$2.96B
1 W Prestazione:
-1.61%
1M Prestazione:
+8.23%
6M Prestazione:
-19.19%
1 anno Prestazione:
-49.27%
Intervallo 1D:
$542.01
$554.48
Intervallo di 1 settimana:
$542.01
$575.13
Portata 52W:
$476.49
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
551.01 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.88 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.26 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron and Sanofi’s Phase 3 Study on Itepekimab: A Potential Game Changer for Chronic Rhinosinusitis - TipRanks
Regeneron’s Promising Obesity Treatment Study: A Potential Game-Changer? - TipRanks
Red Biotechnology Market Attracts Investments from Major - openPR.com
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Boosted by Concord Wealth Partners - MarketBeat
Cullen Frost Bankers Inc. Has $4.36 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Arizona State Retirement System - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Cutter & CO Brokerage Inc. - MarketBeat
Apollon Wealth Management LLC Acquires 1,772 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating - MSN
Retinal Vein Occlusion Market Trends: Surge in Anti-VEGF - openPR.com
Grandfield & Dodd LLC Acquires 611 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Unexpected Trends Reshaping the Diabetic Retinopathy Market - openPR.com
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks
CenterBook Partners LP Sells 10,270 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sumitomo Life Insurance Co. Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Concord Asset Management LLC VA Has $1.33 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Leo Wealth LLC Buys 544 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
1 Healthcare Stock on Our Buy List and 2 to Brush Off - Yahoo Finance
Envestnet Asset Management Inc. Purchases 25,589 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
23andMe Co-Founder Anne Wojcicki Wins Back Company In $305M Deal, Beating Regeneron’s Bid - MSN
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00 at UBS Group - MarketBeat
ANGPTL3 Therapy Market Rises with Focus on Cardiovascular - openPR.com
OVERSEA CHINESE BANKING Corp Ltd Invests $30.17 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
685 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Asahi Life Asset Management CO. LTD. - MarketBeat
Slow Capital Inc. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
710 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by MQS Management LLC - MarketBeat
New York State Common Retirement Fund Sells 6,846 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Wet Age-Related Macular Degeneration (Wet AMD) Market Analysis Report 2025-2035 | Long-Acting Therapies, AI Diagnostics, and Personalized Medicine Set to Redefine the Future Landscape - GlobeNewswire Inc.
Rehmann Capital Advisory Group Acquires 770 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA Action Alert: Roche, GSK, Regeneron, More - BioSpace
Nisa Investment Advisors LLC Has $30.03 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Oxbow Advisors LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN). - MSN
SteelPeak Wealth LLC Has $2.29 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Research Analysts Set Expectations for REGN FY2026 Earnings - MarketBeat
Accelerated FDA Approval of Lynozyfic May Change the Case for Investing in Regeneron (REGN) - simplywall.st
Amgen Eyes New Trial After Regeneron's $407M Antitrust Win - Law360
Lobbying Update: $30,000 of REGENERON PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
2 Firms Tapped To Lead Regeneron Investor Suit - Law360
UBS Raises Price Target on Regeneron Pharmaceuticals to $584 From $560, Keeps Neutral Rating - MarketScreener
DekaBank Deutsche Girozentrale Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target - Yahoo Finance
Impax Asset Management Group plc Sells 1,385 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Assessing Regeneron Pharmaceuticals: Insights From 26 Financial Analysts - Nasdaq
Mcdonald Capital Investors Inc. CA Acquires 26,593 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025 (NASDAQ:REGN) - Seeking Alpha
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by China Universal Asset Management Co. Ltd. - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Bank of New York Mellon Corp Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron’s Blockbuster Dupixent Faces a New Rival - Barron's
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.33%
1.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):